Article
Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review.
Cancer chemotherapy and pharmacology - 1 Jan 2018
Miyamoto Morikazu, Takano Masashi, Kuwahara Mika, Soyama Hiroaki, Kato Kento, Matuura Hiroko, Sakamoto Takahiro, Takasaki Kazuki, Aoyama Tadashi, Yoshikawa Tomoyuki, Furuya Kenichi
Abstract excerpt
PURPOSE: We aimed to retrospectively evaluate the efficacy and toxicity of an irinotecan hydrochloride (CPT) and nedaplatin (N) combination therapy for recurrent and refractory endometrial carcinoma, administered based on UGT1A1 genotype. METHODS: Between 2009 and 2017, 21 patients who received CPT-N therapy for recurrent endometrial carcinoma as second- or third-line chemotherapy at our hospital were identified....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.